admin | November 5, 2022
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association CongressĀ for Preclinical Data on Novel Allosteric BCR-Abl Inhibitor Tern-701
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates